

Index

A

Abacavir/lamivudine (ABC/3TC), 63
Abdominal lymphadenopathy, 45
Acalculous cholecystitis, 25
Acid fast bacteria (AFB), 183
Acquired immunodeficiency syndrome (AIDS), 25, 70
Active antiretroviral therapy (ART), 26
Acute hepatitis A virus (HAV) infection, 114
Acute HIV infection, 135, 136
Acute pancreatitis, 135, 136
Adenovirus, 61, 62
AIDS cholangiopathy
 ART, 26
 atazanavir, 29
 Burkitt lymphoma, 29
 clinical presentation of, 26
 diagnostic testing, 30, 31
 ERCP, 32
 intra- and extra-hepatic ductal dilatation, 29
 KS, 29
 lymphomas, 29
 MRCP, 32
 opportunistic
 bacterial, 26–27
 viral, 28
 fungal, 27
 parasites/protozoan, 27–28
 pathogenesis of, 26
 procedural/surgical, 33
 prognosis of, 33
 sphincter dysfunction, 26
 therapy, 32
 UDP-glucuronyl-transferase, 29
 vanishing bile duct syndrome, 28

AIDS-defining illness, 113
Alanine aminotransferase (ALT), 39, 93
Alcian Blue, 42
American Association for the Study of Liver Diseases (AASLD), 107
American College of Gastroenterology (ACG), 174
Anal intraepithelial lesion (AIN), 176
Anorectal HPV infection, 176
Antigenuria, 44
Antiretroviral therapy (ART), 40, 63, 149, 101, 111
Antiviral therapy, 98
Aperistaltic esophagus, 8
Aspartate aminotransferase (AST), 39, 93
Aspergillus spp., 142
Atazanavir, 29
Azithromycin, 71

B

Bartonella henselae, 53
Bartonella quintana, 53
B cell lymphomas, 58
B-D-glucan, 46
Bezlotoxumab, 178
Biliary and gallbladder disease, 25
Blood cultures, 30
Burkitt lymphoma, 29
Buschke-Lowenstein disease, 176

C

Candida spp., 45, 142
Capreomycin, 69

- Centers for Disease Prevention and Control, 52
- Chlamydia trachomatis* (CT), 179
- Chronic HCV infection, 114
- Chronic HEV infection, 97
- Clarithromycin, 71
- Clostridium difficile* infection (CDI), 163, 164, 177–179
- Coccidioidomycosis, 160, 161
- Colon and rectum disorders
- acid fast organisms
 - MAC, 183, 184
 - MTB infection, 182, 183
 - bacterial infections
 - CDI, 177–179
 - Chlamydia trachomatis*, 179, 180
 - Neisseria gonorrhoea*, 179, 180
 - shigella, 180, 182
 - dysenteric diarrhea, 174
 - HC infection, 187, 188
 - intestinal protozoa
 - amoebiasis, 186, 187
 - cryptosporidium, 185
 - cyclosporiasis, 186
 - cystisporiasis, 185, 186
 - entamoeba, 186
 - microsporidia, 184
 - PCR, 174
 - PLWH, 173
 - stool cultures, 174
 - viral infections
 - CMV, 174, 175
 - HPV, 175–177
 - watery diarrhea, 174
- Computed tomography (CT) imaging, 31, 45, 47
- Condyloma acuminatum, 176
- Cresyl violet stain, 30
- Cryptococcosis, 141
- Cryptococcus neoformans*, 14, 28
- Crypto-Giardia K-SeT®, 185
- Cryptosporidium* spp., 12, 13, 27, 143, 155, 156, 184, 185
- Cutaneous manifestations, 39, 55
- Cyclophosphamide, 8
- Cycloserine, 69
- Cyclospora cayetanensis*, 28, 159
- Cyclospora* oocysts, 159
- Cyclosporiasis, 185
- Cystoisospora*, 158
- Cytomegalovirus (CMV), 13, 15, 27, 58–60, 139, 174, 175
- D**
- Daclatasvir, 119
- Dawson criteria, 8
- Deltavirus*, 110
- Department of Health and Human Services (DHHS) guidelines, 105
- Desert rheumatism, 44
- Direct-acting antiviral agent (DAA) therapy, 116, 122
- Direct fluorescent antibody (DFA), 61
- Direct fluorescent microscopy examination (DFME), 48
- Doxorubicin, 8
- Drug induced liver injury (DILI), 67, 68, 71
- Dysenteric diarrhea, 174
- Dysphagia, 3
- E**
- Eclampsia, 97
- Endoscopic sphincterotomy, 33
- Enertocytozoon bieneusi*, 28
- Entamoeba, 186
- Entecavir, 106, 108
- Enterocytozoon bieneusii*, 184
- Enterocytozoon intestinalis*, 28
- Enzyme immunoassays (EIAs), 44, 115
- Enzyme-linked immunosorbent assay (ELISA), 42, 164
- Eosin, 42
- Epstein Barr Virus (EBV), 57, 58
- Esophageal candidiasis, 2
- Esophagus disorders
- clinical presentation, 1
 - Dawson criteria, 8
 - Kodsi severity grading, 3, 7
 - noninfectious etiologies
 - lymphoma, 7, 8
 - motility disorders, 8
 - non-AIDS defining factors, 8
 - opportunistic infections
 - CMV, 4, 5
 - esophageal candidiasis, 2
 - herpesviridae family, 4
 - HHV-8, 5, 6
 - Histoplasma capsulatum*, 2, 3
 - HSV infections, 5
 - IEUs, 6
 - mycobacterial infections, 4
- Ethambutol (EMB), 68, 69
- Extra-pulmonary tuberculosis, 55

F

- Fanconi syndrome, 150
- Fecal microbiota transplantation (FMT), 178, 179
- FibroSure, 116
- Fluorescent treponemal antibody absorption (FTA-Abs), 14
- Fontana-Masson, 42

G

- Ganciclovir, 150
- Gastric adenocarcinoma, 19
- Gastric lymphoma, 18, 19
- Gastrointestinal bleeding, 52
- Gastrointestinal listeriosis, 164
- Gastrointestinal tuberculosis, 153
- Giardia lamblia*, 28
- GI tract, HIV-infected patients
 - gastric adenocarcinoma, 19
 - gastric fluid, 12
 - gastric lymphoma, 18, 19
 - immune-epithelial interactions, 12
 - KS, 17, 18
 - mucosal surface, 11
 - opportunistic infections
 - CMV infection, 13
 - Cryptococcus neoformans*, 14
 - Cryptosporidium*, 12, 13
 - HAART, 12
 - Helicobacter pylori*, 15, 16
 - syphilis, 14
 - visceral leishmaniasis, 13
 - primary non Hodgkin lymphoma, 18
 - pro-inflammatory cytokines, 11
 - rate of new infection, 11
- Glutamate dehydrogenase (GDH) enzyme, 164, 177
- Glutathione, 69
- Gomori methenamine silver (GMS) stains, 3, 42, 141
- Goose neck deformity, 154
- Grovott-Gomori silver stain, 30
- Guillain-Barré syndrome, 93, 97

H

- Helicobacter pylori* (HP), 15, 16
- Hematoxylin, 42
- Hematoxylin-eosin staining, 175
- Hepatic tuberculosis, 56
- Hepatitis A virus (HAV), 91
 - acute liver disease, 93
 - chronic liver disease, 93
 - clinical presentation of, 93
 - complications, 93
 - early symptoms of, 92
 - epidemiology of, 92
 - prevention of, 94, 95
 - sign of disease, 93
- Hepatitis B immune globulin (HBIG), 108
- Hepatitis B virus (HBV), 66, 99
 - clinical manifestations, 101–103
 - diagnosis of, 103, 104
 - epidemiology, 100–101
 - immune-active phase, 100
 - immune-tolerant phase, 100
 - management of
 - acute hepatitis B, 104–105
 - chronic hepatitis B, 105–106
 - monitoring and treatment duration, 106–107
 - natural history of, 99–100
 - in pregnancy, 108
 - prevention, 108–109
 - screening for HCC, 107–108
 - seroconversion, 100
- Hepatitis C virus (HCV) infection, 66, 111
 - advanced liver disease, 118
 - ART, 111, 117
 - clinical manifestations, 114–115
 - DAA therapy, 117, 122
 - daclatasvir + sofosbuvir, 119
 - diagnosis of, 115–116
 - elbasvir/grazoprevir, 119
 - epidemiology and transmission, 113–114
 - glecaprevir/pibrentasvir, 119–120
 - HCV genotype, 117, 118
 - HIV, 117–118
 - individual genetic heterogeneity, 111
 - ledipasvir/sofosbuvir, 120
 - liver fibrosis and necrosis, 117
 - liver-related mortality, 117
 - liver transplantation, 117
 - natural history and pathogenesis, 112–113
 - noninvasive testing, 116
 - paritaprevir/ritonavir/ombitasvir + dasabuvir, 120–121
 - pegylated interferon, 118
 - positive-strand RNA virus, 111
 - post treatment follow-up, 123
 - screening, 115
 - serum creatinine, 117
 - simeprevir/sofosbuvir, 121
 - sofosbuvir-containing regimens, 118
 - sofosbuvir/velpatasvir, 121–122
 - sofosbuvir/velpatasvir/voxilaprevir, 122
 - transmission of, 117

Hepatitis D virus (HDV), 99, 110, 111
 Hepatitis E virus (HEV), 91
 clinical manifestations, 97
 diagnosis of, 97–98
 epidemiology and modes of transmission, 95–96
 pathogenic mechanisms of, 96
 therapy and prevention, 98–99
 Hepatobiliary (HIDA) scanning, 31, 99, 101, 111
 Hepatocellular carcinoma (HCC), 92
 Hepatocellular injury, 71
 Hepatotoxicity, 69
 Herpes simplex virus (HSV), 5, 60, 139, 140, 151, 152
 Herpes simplex virus (HSV) 1 and 2, 4, 60
 Herpesviridae family, 4
 Highly active antiretroviral therapy (HAART), 12
 Histoplasma, 30
Histoplasma capsulatum, 2, 3, 27, 37
 Histoplasmosis, 161, 162, 187, 188
 Hodgkin's lymphoma, 28, 58
 Human cytomegalovirus (CMV), 149, 150
 Human herpesvirus-6 (HHV-6), 62, 63
 Human herpes virus 8 (HHV-8), 5, 6, 17, 31, 62, 143, 168
 Human immunodeficiency virus (HIV), 11, 37
 Human leukocyte antigens (HLA), 44
 Human papillomavirus (HPV), 175–177
 Hypersensitivity hepatitis, 65
 Hypersensitivity reaction (HSR), 64
 Hypertriglyceridemia, 137
 Hypertriglyceridemia-induced pancreatitis, 137

I
 Idiopathic esophageal ulcers (IEUs), 6
 Immune reconstitution inflammatory syndrome (IRIS), 47
 Immune reconstitution syndrome (IRIS), 63
 Immunodiffusion (ID) assays, 44
 Immunohistochemical (IHC) techniques, 4
 Immunohistochemistry, 175
 Infectious Diseases Society of America (IDSA) guidelines, 40
 Inflammatory bowel disease (IBD), 167, 179
 International normalized ratio (INR), 117
 Interstitial pneumonitis (LIP), 58
 Intestinal metaplasia (IM), 19
 Invasive cryptococcal infection, 41
 Isolated esophageal lymphoma, 7, 8
Isospora belli, 28

K
 Kaposi's sarcoma (KS), 5–6, 17, 18, 29, 62, 143, 144, 168, 169
 Kaposi's sarcoma associated herpesvirus (KSHV), 143
 Kinyou/Ziehl-Neelson staining, 30
 Kodsi severity grading, 3, 7

L
 Lactose dehydrogenase, 48
 Lateral flow assays (LFA), 42
 Latex agglutination (LA), 42
 Leiomyosarcomas, 58
Listeria monocytogenes, 164, 165
 Liver disorders
 anti-tuberculosis
 anti-TB agents, 70
 CYP2E1, 69
 DILI, 67, 68
 hepatic enzymes, 69
 RIF, 69
 risk of, 67
 bartonella
 clinical presentation, 53, 54
 diagnosis of, 54
 epidemiology, 53
 pathophysiology, 53
 treatment, 54, 55
 candida
 clinical presentation, 46
 diagnosis, 46, 47
 epidemiology, 45, 46
 pathophysiology, 46
 treatment, 47
 coccidioides
 clinical presentations, 44
 diagnosis, 44, 45
 epidemiology, 43
 pathophysiology, 43
 treatment, 45
 cryptococcus
 clinical features of, 42
 diagnosis, 42
 epidemiology, 41
 pathophysiology, 41
 treatment, 42, 43
 histoplasmosis
 clinical presentation, 38, 39
 diagnosis of, 39, 40
 multi-organ dysfunction, 38
 Ohio and Mississippi River valley, 38
 pathophysiology, 38
 treatment, 40, 41

- penicillium
 - clinical presentation, 50
 - diagnosis, 50
 - epidemiology, 49
 - pathophysiology, 49
 - treatment, 50
- Pneumocystis jirovecii*
 - clinical presentation, 48
 - diagnosis, 48
 - epidemiology, 47, 48
 - pathophysiology, 48
 - treatment for, 49
- schistosomiasis
 - clinical presentation, 51, 52
 - diagnosis, 52
 - epidemiology, 50, 51
 - pathophysiology, 51
 - treatment, 52, 53
- Liver toxicity, 63
- Lymphogranuloma venereum (LGV), 179

- M**
- Magnetic resonance imaging (MRI), 47
- Methenamine silver stains, 48
- Metronidazole, 178
- Microsporidia, 157, 184
- Microsporidium, 28
- Microvesicular steatosis, 64
- Miliary tuberculosis, 55
- Mitochondrial toxicity, 64
- Moxifloxacin, 71
- Mucicarmine, 42
- Multidrug resistant (MDR), 69
- Myalgias, 102
- Mycobacteria, 30
- Mycobacterial infections, 4
- Mycobacterium avium complex* (MAC), 4, 26, 71, 140, 154, 155, 183, 184
- Mycobacterium tuberculosis* (MTB), 4, 27, 55, 67, 153, 154, 182

- N**
- N-acetyltransferase 2 (NAT-2), 69
- Nasopharyngeal carcinoma, 58
- Neisseria gonorrhoea* (NG), 179
- NNRTI liver toxicity, 65
- Non-Hodgkin lymphoma (NHL), 7, 29, 58, 144, 169
- Norovirus*, 150, 151
- Nucleoside reverse transcriptase inhibitors (NRTIs), 63, 105, 136, 137

- O**
- Odynophagia, 3
- Opportunistic infections (OIs), 37, 39, 70
- Oral hairy leukoplakia (OHL), 58

- P**
- Pancreas disorders
 - Aspergillus* spp., 142
 - Candida* spp., 142
 - cryptococcosis, 141
 - Cryptosporidium* spp., 143
 - etiology/differential diagnosis of, 136
 - Kaposi's sarcoma, 143, 144
 - MAC, 140
 - mycobacterium tuberculosis, 140
 - NHL, 144
 - NRTIs, 136, 137
 - opportunistic infections
 - cytomegalovirus, 139
 - HSV, 139, 140
 - pentamidine isethionate, 138
 - PIs, 137, 138
 - Pneumocystis jirovecii*, 141
 - Toxoplasma gondii*, 143
 - trimethoprim-sulfamethoxazole, 138, 139
- Paromomycin, 186
- Patients living with HIV infection (PLWH), 173
- Pegylated liposomal doxorubicin (PLD), 18
- Penicillium marneffei*, 49, 50
- Persons living with HIV (PLWH), 99
- Pneumocystis jirovecii* pneumonia (PJP)
 - prophylaxis, 27, 70, 141
- Polyarteritis nodosa (PAN), 102
- Polymerase chain reaction (PCR) assays, 44, 46, 48, 159
- Postexposure prophylaxis, 109
- Post-transplant lymphoproliferative disorders, 58
- Prednisone, 8
- Primary central nervous system lymphoma (PCL), 58
- Primary gastrointestinal lymphoma, 7–8
- Protease inhibitors (PIs), 65, 137, 138
- Pyrazinamide (PZA), 67, 68

- R**
- Radiologic imaging, 47
- Rapid diagnostic tests (RDTs), 185
- Rapid plasma reagin (RPR), 14
- Raynaud's syndrome, 102

Ribavirin and interferon (IFN)- α , 98
 Rifabutin, 71
 Rifampin (RIF), 67, 68
 Routine postvaccination serologic testing, 95

S

Schistosoma haematobium, 51
Schistosoma japonicum, 51, 52
Schistosoma mansoni, 51, 52
 Seroconversion, 100, 105, 109
 Serological testing, 54
 Serum beta-D-glucan, 48
 Sexually transmitted infections (STIs), 179
Shigella spp., 151, 180, 182
 Single-agent rituximab, 19
 Sjogren's syndrome, 102
 Small bowel disorders
 bacterial infections
 C. difficile, 163, 164
 enterobacteriaceae, 162, 163
 L. monocytogenes, 164, 165
 Vibrio cholerae, 165
 fungal infections
 coccidioidomycosis, 160, 161
 histoplasmosis, 161, 162
 helminthic infections, strongyloides
 stercoralis, 166, 167
 malignancy
 KS, 168, 169
 NHL, 169
 mycobacterial infections
 MAC, 154, 155
 MTB, 153, 154
 non-infectious
 HIV/AIDS enteropathy, 168
 IBD, 167
 parasitic infections
 Cryptosporidium, 155, 156
 Cyclospora, 159
 Cystoisospora, 158
 microsporidia, 157
 Toxoplasma gondii, 160
 viral infections
 adenoviruses, 152
 CMV, 149, 150
 HSV infections, 151, 152
 norovirus, 150, 151
 Solid organ transplantation (SOT), 45
 Sphincter dysfunction, 26
 Stevens Johnson syndrome, 66
 Stool testing, 30
 Streptomycin, 69

Strongyloides stercoralis, 166, 167
 Symmer's fibrosis, 51
 Syphilis, 14

T

Tacrolimus, 98
Talaromyces spp., 49
 T cell lymphoma, 58
 Tenofovir, 64, 108
 Tenofovir alafenamide (TAF), 63, 105
 Tenofovir disoproxil fumarate (TDF),
 63, 105, 120
 Thiosulfate citrate bile salts sucrose
 (TCBS), 165
 Toluidine blue O stain, 30
Toxoplasma gondii, 143, 160
 Toxoplasmosis prophylaxis, 71
 Trench fever, 53
 Treponema pallidum hemagglutination test
 (TPHA) test, 14
 Trichloroacetic acid, 176
 Trimethoprim-sulfamethoxazole
 (TMP/SMX), 49

U

Ulcerative colitis (UC), 167
 Ultrasound, 31
 Ursodeoxycholic acid (URSO), 32

V

Valganciclovir, 150
 Vancomycin, 178
 Vanishing bile duct syndrome, 28
 Venereal disease research laboratory antibody
 (VDRL), 14
Vibrio cholerae, 165
Vibrio parahaemolyticus, 165
 Vincristine, 8
 Viral-envelope protein, 11
 Viral hepatitis
 diagnosis and management, 93, 94
 HAV
 acute liver disease, 93
 chronic liver disease, 93
 clinical presentation of, 93
 complications, 93
 early symptoms of, 92
 epidemiology of, 92
 prevention of, 94, 95
 sign of disease, 93

HBV

- acute hepatitis B, management of, 104–105
- chronic hepatitis B, management of, 105–106
- clinical manifestations, 101–103
- diagnosis of, 103, 104
- epidemiology, 100–101
- immune-active phase, 100
- immune-tolerant phase, 100
- monitoring and treatment duration, 106–107
- natural history of, 99–100
- in pregnancy, 108
- prevention, 108–109
- screening for HCC, 107–108
- seroconversion, 100

HCV

- advanced liver disease, 118
- ART, 111, 117, 118
- clinical manifestations, 114–115
- DAA therapy, 117, 122
- daclatasvir + sofosbuvir, 119
- diagnosis of, 115–116
- elbasvir/grazoprevir, 119
- epidemiology and transmission, 113–114
- glecaprevir/pibrentasvir, 119–120
- HCV genotype, 117, 118
- HIV treatment, 117–118
- individual genetic heterogeneity, 111
- ledipasvir/sofosbuvir, 120

- liver fibrosis and necrosis, 117
- liver-related mortality, 117
- liver transplantation, 117
- natural history and pathogenesis, 112–113
- noninvasive testing, 116
- paritaprevir/ritonavir/ombitasvir + dasabuvir, 120–121
- pegylated interferon, 118
- positive-strand RNA virus, 111
- post treatment follow-up, 123
- screening, 115
- serum creatinine, 117
- simeprevir/sofosbuvir, 121
- sofosbuvir-containing regimens, 118
- sofosbuvir/velpatasvir, 121–122
- sofosbuvir/velpatasvir/voxilaprevir, 122
- transmission of, 117

HEV

- clinical manifestations, 97
 - diagnosis of, 97–98
 - epidemiology and modes of transmission, 95–96
 - pathogenic mechanisms of, 96
 - therapy and prevention, 98–99
- Visceral leishmaniasis (VL), 13

W

- Warthin-Starry Silver stains, 54
- Watery diarrhea, 174
- Wright-Giemsa staining techniques, 143